Drug Approval | April 24, 2023
USFDA suggests corrective measures to Sun Pharmaceutical’s Mohali facility
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
Science communication brings behavioural changes
India's strategy against Covid was more effective than any other countries in the world
Subscribe To Our Newsletter & Stay Updated
